Market Overview

Glaukos Announces Pharmaceutical Development Agreement with D. Western Therapeutics Institute, Inc.

Share:

Collaboration with Preeminent Rho Kinase (ROCK) Inhibitor R&D
Organization to Explore Novel Compounds for Glaukos' iDose
TM
Drug Delivery System

Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and
pharmaceutical company focused on the development and commercialization
of novel surgical devices and sustained pharmaceutical therapies
designed to transform the treatment of glaucoma, today announced it has
entered into a research and development collaboration agreement with D.
Western Therapeutics Institute (DWTI), a Japanese biotechnology company
focused on the discovery and development of innovative new drugs to
serve patients worldwide.

Under the agreement, Glaukos and DWTI will conduct joint research for
the development of novel intraocular products for the treatment of
glaucoma using compounds from DWTI's proprietary ROCK inhibitor compound
library, one of DWTI's fundamental technologies, and potentially design
and synthesize new compounds for this collaboration. Glaukos will
conduct the evaluation and development of the compounds.

"We are delighted to enter into this collaboration with D. Western,
which has a proven track record of novel drug discovery and is highly
regarded in the industry as the preeminent research organization for
proprietary ROCK inhibitor compounds," said Thomas Burns, Glaukos
president and chief executive officer. "We are excited to commence the
initial phases of this collaborative research effort to explore
potential new compounds that may be used in our novel iDoseTM
drug delivery system in order to expand and improve the treatment of
glaucoma."

Per the agreement, DWTI will receive an upfront technology access fee
and research support fees from Glaukos. In addition, if one or more
candidate compounds are identified, Glaukos holds the exclusive right to
develop novel intracameral and topical products using the compounds
through a licensing arrangement with DWTI.

Glaucoma is characterized by progressive, irreversible and largely
asymptomatic vision loss caused by optic nerve damage. There is no cure
for the disease and reducing IOP is the only proven treatment. Based on
analysis of population-based surveys, medical claims data and other
statistics, the company estimates that there are approximately 5.4
million people in the U.S. with primary open-angle glaucoma, the most
common form of the disease.

About D. Western

D. Western Therapeutics Institute is a Japanese biotechnology company
that focuses on the discovery and development of innovative new drugs to
serve patients worldwide. Its research and development laboratory
undertakes drug design, screening of compounds and selection of prospect
compounds at early stages of the drug research and development process.
DWTI's seed compounds are inhibitors of protein kinases the company has
accumulated in the past. The company creates effective drug candidate
compounds by advancing development of such inhibitors that control the
function of the protein kinase. The company was founded by Hiroyoshi
Hidaka in February 1999 and is headquartered in Nagoya, Japan. Shares of
DWTI are publicly traded on the Tokyo Stock Exchange (TSE).

About Glaukos

Glaukos (www.glaukos.com)
is an ophthalmic medical technology and pharmaceutical company focused
on the development and commercialization of novel surgical devices and
sustained pharmaceutical therapies designed to transform the treatment
of glaucoma, one of the world's leading causes of blindness. The company
pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the
traditional glaucoma treatment and management paradigm. Glaukos launched
the iStent®, its first MIGS device, in the
United States in July 2012 and is leveraging its platform technology to
build a comprehensive and proprietary portfolio of micro-scale
injectable therapies designed to address the complete range of glaucoma
disease states and progression. The company believes the iStent inject®,
measuring 0.23 mm wide and 0.36 mm long, is the smallest medical device
ever approved by the FDA.

Forward-Looking Statements

All statements other than statements of historical facts included in
this press release that address activities, events or developments that
we expect, believe or anticipate will or may occur in the future are
forward-looking statements. Although we believe that we have a
reasonable basis for forward-looking statements contained herein, we
caution you that they are based on current expectations about future
events affecting us and are subject to risks, uncertainties and factors
relating to our operations and business environment, all of which are
difficult to predict and many of which are beyond our control, that may
cause our actual results to differ materially from those expressed or
implied by forward-looking statements in this press release. These
potential risks and uncertainties include, without limitation, the
extent to which the joint research to be conducted by Glaukos and DWTI
pursuant to the research and development agreement will result in the
development of any novel intraocular products or compounds for the
treatment of glaucoma; and the extent to which Glaukos will be able to
develop or otherwise obtain any new compounds that may be used in our
novel iDoseTM drug delivery system; and whether
Glaukos would obtain the necessary regulatory approvals to commercialize
any new compounds. These risks, uncertainties and factors are described
in detail under the caption "Risk Factors" and elsewhere in our filings
with the Securities and Exchange Commission, including our Quarterly
Report on Form 10-Q for the quarter ended March 31, 2018 filed with the
Securities and Exchange Commission. Our filings with the Securities and
Exchange Commission are available in the Investor Section of our website
at www.glaukos.com
or at www.sec.gov.
In addition, information about the risks and benefits of our products is
available on our website at www.glaukos.com.
All forward-looking statements included in this press release are
expressly qualified in their entirety by the foregoing cautionary
statements. You are cautioned not to place undue reliance on the
forward-looking statements in this press release, which speak only as of
the date hereof. We do not undertake any obligation to update, amend or
clarify these forward-looking statements whether as a result of new
information, future events or otherwise, except as may be required under
applicable securities law.

View Comments and Join the Discussion!